التفاصيل البيبلوغرافية
| العنوان: |
In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV1 reversibility |
| المؤلفون: |
J. Christian Virchow, Lisa Hickey, Evelyn Du, Margaret Garin |
| المصدر: |
Allergy, Asthma & Clinical Immunology, Vol 16, Iss 1, Pp 1-8 (2020) |
| بيانات النشر: |
BMC, 2020. |
| سنة النشر: |
2020 |
| المجموعة: |
LCC:Immunologic diseases. Allergy |
| مصطلحات موضوعية: |
Asthma, Clinical trials, Eosinophils, Lung function, Immunologic diseases. Allergy, RC581-607 |
| الوصف: |
Abstract Background A post hoc analysis of two randomized, placebo–controlled, Phase 3 trials of intravenous reslizumab, an anti-interleukin-5 (IL-5) biologic for severe eosinophilic asthma. Methods Relationships between baseline blood eosinophil levels (EOS), forced expiratory volume in 1 s (FEV1) reversibility to β2-agonists and treatment outcomes were assessed. Results Mean baseline FEV1 reversibility was numerically lower among patients with high (≥ 400 cells/µL) versus low baseline EOS. Reslizumab produced clinically significant improvement in FEV1, exacerbation rates and patient-reported outcomes after 52 weeks, including in patients with high EOS and low FEV1 reversibility (≤ 14%) to β2-agonists at baseline. Conclusions Clinical trial eligibility criteria stipulating minimum FEV1 reversibility to β2-agonists of ≥ 12% might exclude patients who would benefit from treatment with anti-IL-5 biologics. |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
1710-1492 |
| Relation: |
http://link.springer.com/article/10.1186/s13223-020-00424-2; https://doaj.org/toc/1710-1492 |
| DOI: |
10.1186/s13223-020-00424-2 |
| URL الوصول: |
https://doaj.org/article/50d1273204b643ed93e6c67328950ea6 |
| رقم الانضمام: |
edsdoj.50d1273204b643ed93e6c67328950ea6 |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder